Lymphoseek

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial Timeline

May 1, 2009 → Aug 1, 2013

About Lymphoseek

Lymphoseek is a phase 3 stage product being developed by Navidea Biopharmaceuticals for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is terminated. This product is registered under clinical trial identifier NCT00911326. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).

What happened to similar drugs?

11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved

Approved (11) Terminated (0) Active (9)

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01106040Phase 3Completed
NCT00911326Phase 3Terminated
NCT00671918Phase 3Completed

Competing Products

20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40